[email protected]/(408) 457-3700

About Prometheus Metabolomics ltd

The study of the small-molecules (a.k.a. metabolites) has shown considerable promises in disease diagnosis and biomarkers discovery. Precise metabolite quantification is a prerequisite to move any chemical biomarker or biomarker panel from the laboratory to the clinic. PROMETHEUS METABOLOMICS LTD makes progress toward fully automated and reliable metabolite quantification for an efficient high-throughput tool of clinical analysis. Using NMR spectroscopy and advanced methods of data analysis, PROMETHEUS METABOLOMICS LTD offers an extensive portfolio of services for metabolite analysis in biological samples (e.g. urine, plasma/serum, faecal extract, tissue).

Technology Overview

The emergence of personalised and precision healthcare requires detailed knowledge of human molecular pathology. The concentrations of small molecules (a.k.a. metabolites), such as lipids, oligopeptides, nucleotides, amino acids, sugars and metabolic intermediates, represent a snapshot of the metabolic dynamic that reflects the response of living systems to environmental factors, pathophysiological stimuli (e.g. cardiovascular diseases) or genetic modifications (e.g. cancer). This information can be extracted from a biofluid (i.e. urine and blood) or a tissue by NMR spectroscopy. However, due to its complexity, NMR profiling has remained manual resulting slow, expensive and errorprone procedure that have hindered its clinical and industrial usage. Current preclinical methods are limited in predicting successful outcomes. Such failure exacts enormous cost, both financial and in the quality of human life. Drug development and preclinical trials are challenging processes and more than 80% to 90% of drug candidates fail to gain approval from the US Food and Drug Administration. Predictive and efficient tools are required to discover high quality targets and increase the probability of success in the process of new drug development. One such solution to the challenges faced in the development of new drugs and combination therapies is the use of low-cost and high-throughput experiments specifically designed for animal models. New technological innovations are improving the process of preclinical testing by generating richer data, resulting in higher validation of results.

PROMETHEUS METABOLOMICS LTD makes progress toward fully automated and reliable metabolite quantification for an efficient high-throughput tool of clinical analysis. The study of the ensemble of all metabolites (metabolomics) by NMR spectroscopy has shown considerable promise in disease diagnosis and biomarker discovery in both biofluids and tissues. Precise metabolite quantification is a prerequisite to move any chemical biomarker or biomarker panel from the laboratory to the clinic

You need to register as an accredited investor before we can show you the details of any investment opportunities.

VentureHealth is currently invite only.

Request An Invite!

Startup's Info

Location:
London
Markets:
Biotechnology, Pharmaceuticals, Diagnostics, Healthcare Services
Uploaded Files: